Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Yervoy